Nicola J. Curtin

Overview

Best Publications

• Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase

  Helen E. Bryant;Nilklas Schultz;Huw D. Thomas;Kayan M. Parker

  5582
  Citations

• Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM.

  Ian Hickson;Yan Zhao;Caroline J. Richardson;Sharon J. Green

  1421
  Citations

• Anticancer Chemosensitization and Radiosensitization by the Novel Poly(ADP-ribose) Polymerase-1 Inhibitor AG14361

  Christopher R. Calabrese;Robert Almassy;Stephanie Barton;Michael A. Batey

  588
  Citations

• Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer.

  Suzanne A. Eccles;Eric O. Aboagye;Simak Ali;Annie S. Anderson

  523
  Citations

• Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441

  Yan Zhao;Huw D. Thomas;Michael A. Batey;Ian G. Cowell

  507
  Citations

• Radiosensitization and DNA Repair Inhibition by the Combined Use of Novel Inhibitors of DNA-dependent Protein Kinase and Poly(ADP-Ribose) Polymerase-1

  Unknown

  430
  Citations

• Resistance-modifying agents. 9. Synthesis and biological properties of benzimidazole inhibitors of the DNA repair enzyme poly(ADP-ribose) polymerase

  Alex William White;Robert Almassy;A. Hilary Calvert;Nicola J. Curtin

  385
  Citations

• Preclinical selection of a novel poly(ADP-ribose) polymerase inhibitor for clinical trial

  Huw D. Thomas;Christopher R. Calabrese;Michael A. Batey;Stacie Canan

  358
  Citations

• Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition

  Neil Johnson;Yu-Chen Li;Zandra E Walton;Katherine A Cheng

  305
  Citations

• Structure-based design of a potent purine-based cyclin-dependent kinase inhibitor

  T.G Davies;J Bentley;C.E Arris;F.T Boyle

  290
  Citations

• Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2

  Unknown

  290
  Citations

• Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines

  C A Delaney;L Z Wang;S Kyle;A W White

  282
  Citations

• Targeting the ATR-CHK1 Axis in Cancer Therapy

  Unknown

  243
  Citations

• Novel Poly(ADP-ribose) Polymerase-1 Inhibitor, AG14361, Restores Sensitivity to Temozolomide in Mismatch Repair-Deficient Cells

  Nicola J. Curtin;Lan-Zhen Wang;Anthie Yiakouvaki;Suzanne Kyle

  225
  Citations

• DNA damage checkpoint kinases in cancer

  223
  Citations

• Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro

  Karen Julia Bowman;D. R. Newell;A. H. Calvert;N. J. Curtin

  207
  Citations

• Discovery of Potent Chromen-4-one Inhibitors of the DNA-Dependent Protein Kinase (DNA-PK) Using a Small-Molecule Library Approach

  Ian R Hardcastle;Xiaoling Cockcroft;Nicola J Curtin;Marine Desage El-Murr

  206
  Citations

• Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases

  Nathan A Berger;Valerie C Besson;A Hamid Boulares;Alexander Bürkle

  195
  Citations

• Preclinical evaluation of a novel ATM inhibitor, KU59403, in vitro and in vivo in p53 functional and dysfunctional models of human cancer

  Michael A. Batey;Yan Zhao;Suzanne Kyle;Caroline Richardson

  192
  Citations

• Cyclin dependent kinase inhibitors

  Francis Thomas Boyle;Alan Hilary Calvert;Nicola Jane Curtin;Jane Anne Endicott

  143
  Citations